New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 8, 2012
11:18 EDTRHHBYRoche unit Genentech's Perjeta shows extended survival in breast cancer patients
Genentech, a member of the Roche Group (RHHBY), announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta, Herceptin and docetaxel chemotherapy significantly extended the overall survival of people with previously untreated HER2-positive metastatic breast cancer, compared to Herceptin, chemotherapy and placebo. Results showed that the risk of death was reduced by 34% for people who received Perjeta, Herceptin and chemotherapy, compared to those who received Herceptin and chemotherapy. At the time of the analysis, median overall survival had not yet been reached in people receiving the Perjeta combination, as more than half of these people continued to survive. Median overall survival was 37.6 months for people who received Herceptin and chemotherapy. Based on these data, people receiving Herceptin and chemotherapy in CLEOPATRA have been offered the option to receive Perjeta. No new safety signals were observed in the study. :theflyonthewall.com
News For RHHBY From The Last 14 Days
Check below for free stories on RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
05:58 EDTRHHBYExelixis shares rallied on Roche rumors, says Piper Jaffray
Subscribe for More Information
July 28, 2014
07:30 EDTRHHBYQ1 Productions to hold a conference
Subscribe for More Information
July 25, 2014
07:35 EDTRHHBYEMA recommends new indication for RoActemra in severe arthritis
Subscribe for More Information
July 24, 2014
06:13 EDTRHHBYRoche reaffirms outlook for 2014
Subscribe for More Information
06:12 EDTRHHBYRoche reports 1H core EPS CHF 7.57 vs. CHF 7.58 last year
Subscribe for More Information
July 23, 2014
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 22, 2014
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
July 16, 2014
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
05:37 EDTRHHBYGenentech Avastin granted priority review by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use